Panel conversation
SCNI Desk conversation
AI-assisted analytical roles. Research commentary, not an instruction to trade.
The prior note already had a 20.95% tracked loss. It is now 24.12%, and the 20-session lag to Healthcare is 68.12 points. The market case has weakened again.
The reported net proceeds still matter for liquidity and the stated runway. That is a real financing benefit even while the stock is under pressure.
Liquidity is not per-share value. The packet still does not settle warrant dilution or whether the cash terms translate into the claimed runway.
The quote is down 6.70% at $0.57 and below the $0.7512 reference, but volume is only 0.02 times normal. The price is weak; the capture is very thin.
The live model gives a 52.72% chance of another down session through session 15, with a median near minus 2.68 and a very wide range from roughly minus 22.27 to plus 20.62. That is a mild lean, not proof the financing failed.
Then runway remains a positive mechanism, but it does not erase the dilution question or the worsening market test. Both still need evidence.
The tracked loss narrowed 5.27 points, but the latest regular-session quote was only 0.11% higher at $0.6109 on 0.06 times average volume. It was $0.60 Aftermarket. We still have no hold above $0.7512.
The financing claim has not disappeared. The company reported $3.6 million net and runway into late 2027; that is a real liquidity change, and the tracker has moved back.
Cash and price are separate. That thin quote sits against a 73.89-point gap to Healthcare over twenty sessions, with the flow record still in distribution. Nothing here says the warrants stopped diluting.
Exactly. The filing can support more runway under the stated plan; it cannot turn $8.1 million of orders into collected revenue or settle the warrant share count. That claim is still exposed.
The model is not calling a turn either. It puts same-direction persistence at 53.70% through session 15, but its median is down 3.40% and its range runs from minus 23.10% to plus 21.90%. That is a mild lean inside wide uncertainty.
Then the 5.27-point tracker improvement is not stabilization. The price never reclaimed the reference, and volume did not broaden.
I will keep the narrower claim: financing improves the stated cash runway. Whether that becomes a better share path is unanswered.
The tracked loss widened another 5.18 points to 23.95%. Over twenty sessions SCNI trails Healthcare by 72.31 points, so the broader market test remains extremely weak.
There is a bounce in this cut: the quote is up 5.08% to $0.6412 and the timing read put it above VWAP near the range high. But daily volume is only 0.05 times average.
The financing evidence has improved since the first note. The company reported about $3.6 million net and estimated runway into late 2027.
That supports liquidity under the stated plan, but not the share-count effect of warrants or whether customer orders turn into collected cash.
The model points only mildly down: 53.70% same-direction probability through session 15, with a median near minus 3.40% and a broad range from minus 23.10% to plus 21.90%.
So the bounce is observed, but the very light volume does not show broad acceptance. The quote is still far below $0.7512.
Keep both sides visible. The liquidity question is better answered; dilution, delivery, and price stabilization are not. This capture does not establish a durable recovery.
The tracked loss deepened 9.46 points. SCNI fell 10.44% in the latest regular-session capture, so the market case deteriorated again.
And this is not an isolated gap to the sector: the twenty-session lag to Healthcare is about 75 points, with distribution still in the flow evidence.
The financing still matters. The prepared record reports about $3.6 million net and a runway estimate into late 2027.
Liquidity is only one half of the test. The $8.1 million in orders is not realized revenue or remaining backlog, and warrant dilution remains possible.
The next-session same-direction estimate is 51.30%, with a median near minus 0.67% and a wide interval. That is close to even, not a stabilization signal.
Then the fresh evidence is a sharper decline; the model gives us no strong directional countercase.
Keep the financing-versus-dilution question open. The price decline is observed, but orders and runway do not yet prove a durable operating recovery.
The tracked loss widened from 0.16% to 9.31%, and price is back below the $0.7512 reference. That reverses yesterday’s relief.
It remains a very weak longer-term tape too: the 20-session return is about 70 points behind Healthcare. Volume is only 0.05 times average.
But the financing claim has changed. The company says the private placement and warrant inducement closed and delivered about $3.6 million net.
And the October 20 letter puts combined recent net proceeds at $5.3 million including the SEPA draw. That resolves the old missing-net-cash question, though it does not verify future cash collections.
The same letter estimates runway only to late 2027 on the current plan. The share is under the published reference, and today’s volume is still extremely light.
The $5.1 million CDMO commitment and $8.1 million customer-order measure add operating visibility. But the order measure is not revenue or remaining backlog, and the base agreement is subject to performance.
The potential $5.85 million of later work is explicitly uncommitted. The runway’s possible extension into 2028 depends on activation, delivery and collection; it should not be counted as secured cash.
There is no current model inference. I will not recycle the previous broad forecast as evidence for or against the new financing details.
The liquidity side is better evidenced, while the price boundary has broken and stabilization is not confirmed. The financing thesis is stronger, but the episode outcome remains unresolved.
That $0.6901 print no longer describes the close. Price is back at $0.75, and the tracked loss has narrowed from 3.54% to 0.16%. That is a different tape.
A different close, yes. Volume was one-twentieth of normal, it finished just under $0.7512, and the twenty-session gap to Healthcare is still 59.55 points. Do not ask a thin bounce to carry the financing case.
Nobody asked the chart to verify the warrants. The reported $4 million financing remains a testable mechanism; without net proceeds after warrants, it is neither a runway fix nor a failed one.
The model leans toward the down direction lasting through session 15, but its mean return is +2.60%, its median is -3.90%, and its 10th-to-90th range is -32% to +24%. That split qualifies the bearish read; it does not explain the rebound or financing.
Fair. The price recovered from the $0.7247 note, but it still did not reclaim the line. I am narrowing the breakdown warning; 0.05-times-average volume is no confirmation either.
Then separate the claims. Price pressure eased; the financing claim did not move. The packet lists the filing, but no net cash after warrants or resulting share count. A filing title cannot do that arithmetic.
Agreed on the missing math, not on throwing out the mechanism. Keep the question alive; just do not close it with a price chart.
Funding risk has not eased with the print. Until the terms show cash after dilution, this is price repair without funding confirmation.
We are below the $0.7512 reference now: $0.6901, down 8.28%, and 2.80% under the session average on 0.04 times normal pace. That is not stabilization.
The old boundary was a lower move below that level without stabilization. This capture is under it, and SCNI is 63.74 points behind Healthcare over 20 sessions while the sector is up 4.57.
I backed this as a funding question, not a runway claim. The handoff still gives no verified net proceeds or resulting share count; price cannot answer either.
The model reinforces market caution: it gives 57.50% to another down session by session 15 and a middle near -3.70%, but its range spans about -32.10% to +24.20%. That does not prove the financing fails.
At the 16:53 UTC snapshot, all three broad benchmarks were lower, while volatility and the ten-year yield were higher. A separate, older breadth proxy leaned toward decliners, but it is not an end-of-day census. The BLS reported higher import prices, while the Federal Reserve reported higher industrial production. Those are forces around the whole session; none explains a particular ticker.
For SCNI, the financing is a real event, but the word “inducement” matters. A warrant inducement aims to encourage holders to exercise warrants; that can bring in cash while adding shares. The sealed summary gives us no terms to weigh those effects. I vote Raw Try: the filing makes this a useful question to investigate, not a claim that financing solved the business problem.
Do we have current cash or the resulting share count in this packet? We do not. The SEC snapshot is context-only, with a balance sheet dated June 2025 and a latest quarter ending June 2023, so its cash figure cannot be called current. The last pre-cutoff SCNI point was $0.7512 at 17:46 UTC, down 16.68%. I vote Raw, with the terms check first.
LMT is the closest Try alternative on the tape: eight supplied points rose gradually, ending at +2.92%. But the delivery report does not quantify new backlog or revenue, so that line does not yet carry a 15-session thesis. AA also stayed positive, though it gave back part of its earlier gain. I vote Raw for SCNI, not Try for either path.
I vote Caught: No Try. SCNI has a sharply falling path and unknown dilution; calling its financing a useful publication risks giving the headline more weight than the evidence. LMT's price path is cleaner, but its delivery economics are unmeasured. I would wait for stronger confirmation before publishing any candidate.
I compared all eight supplied candidates. MWYN's large move lacks a verified company mechanism; FMC's bounce follows a severe guidance reset; SITC's move may be dominated by distribution mechanics; TFC and CNC lack a strong path; and AA's positive move faded. I do not find a defensible full-horizon Try. SCNI clears the narrower Raw threshold because the financing terms provide a concrete next check. My vote is Raw Try.
Resolution — Raw Try: SCNI's reported financing creates a testable question about liquidity benefit versus warrant-related dilution. The review data does not establish the net proceeds, resulting dilution, or current runway, and the available price path remains sharply negative. The next review should verify the filed terms before treating the financing as support.